We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 31, 2023

Lenvatinib and Pembrolizumab for Advanced Endometrial Carcinoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
J. Clin. Oncol 2023 Jan 06;[EPub Ahead of Print], V Makker, C Aghajanian, AL Cohn, M Romeo, R Bratos, MS Brose, M Messing, L Dutta, CE Dutcus, J Huang, EV Schmidt, R Orlowski, MH Taylor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading